Efficacy and Safety of Imetelstat in ESA- ineligible patients

Opinion
Video

  • Please discuss the efficacy and safety findings from IMerge in patients for patients who have sermon EPO levels >500m U/L (ESA ineligible):
  • IMerge (Platzbecker et al. Lancet 2024) (Santini et al. EHA 2024, Abstr. S184)
  • MEDALIST (Fenaux et al. NEJM 2020) (Santini et al. ASH 2023, Abstr. 915)
Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
3 KOLs are featured in this series.
3 KOLs are featured in this series.
Related Content
Study Launches of QXL138AM in Multiple Myeloma and Solid Tumors

Study Launches of QXL138AM in Multiple Myeloma and Solid Tumors

Jordyn Sava
November 15th 2024
Article

Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid tumors and multiple myeloma.

Read More

Mitigating Cardiotoxicity Resulting from Immune Checkpoint Inhibitor Therapy

Mitigating Cardiotoxicity Resulting from Immune Checkpoint Inhibitor Therapy

Nichole Tucker
June 30th 2023
Podcast

In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD, discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.

Listen

Trial of PT886 and Pembrolizumab Doses First Patient With Gastric/GEJ Cancer

Trial of PT886 and Pembrolizumab Doses First Patient With Gastric/GEJ Cancer

Jordyn Sava
October 10th 2024
Article

The first patient with advanced gastric and gastroesophageal cancer has been dosed in a trial combining PT886 with pembrolizumab.

Read More

STX-241 Trial Begins for EGFR TKI-Resistant NSCLC Treatment

STX-241 Trial Begins for EGFR TKI-Resistant NSCLC Treatment

Sabrina Serani
October 8th 2024
Article

The first patient in a phase 1/2 trial investigating a novel agent for the treatment of non–small cell lung cancer has been dosed.

Read More

LP-184 Earns 3 FDA Rare Pediatric Disease Designations in Solid Tumors

LP-184 Earns 3 FDA Rare Pediatric Disease Designations in Solid Tumors

Sabrina Serani
September 24th 2024
Article

The novel agent LP-184 has been granted rare pediatric disease designations in malignant rhabdoid tumors, rhabdomyosarcoma, and hepatoblastoma.

Read More

Phase 2 REMARK Trial of RVU120 Doses First Patient With Lower-Risk MDS

Phase 2 REMARK Trial of RVU120 Doses First Patient With Lower-Risk MDS

Jordyn Sava
September 19th 2024
Article

The REMARK trial aims to assess the safety and efficacy of RVU120 in patients with lower-risk myelodysplastic syndromes.

Read More